SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.19 CNY | +1.35% |
|
+3.02% | -7.35% |
| 04-24 | Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator | MT |
| 04-18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
| Sales 2024 * | 45.05B 6.22B 8.5B | Sales 2025 * | 50.8B 7.01B 9.59B | Capitalization | 55.44B 7.65B 10.46B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.34B 461M 631M | Net income 2025 * | 4.28B 591M 807M | EV / Sales 2024 * | 1.58 x |
| Net Debt 2024 * | 15.69B 2.17B 2.96B | Net Debt 2025 * | 17.77B 2.45B 3.35B | EV / Sales 2025 * | 1.44 x |
| P/E ratio 2024 * |
18.4
x | P/E ratio 2025 * |
14.2
x | Employees | 40,370 |
| Yield 2024 * |
1.8% | Yield 2025 * |
2.11% | Free-Float | 63.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.35% | ||
| 1 week | +3.02% | ||
| Current month | +0.52% | ||
| 1 month | -1.49% | ||
| 3 months | +0.09% | ||
| 6 months | -14.90% | ||
| Current year | -7.35% |
1 week
22.46
23.19
1 month
22.2523.62
Current year
20.3825.89
1 year
20.3832.74
3 years
20.3891.69
5 years
20.3891.69
10 years
16.5091.69
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10-04-08 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 2 M€ | -16.59% | - | |
| 1.18% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 23.19 | +1.35% | 11,252,670 |
| 24-04-25 | 22.88 | +0.66% | 8,754,328 |
| 24-04-24 | 22.73 | -0.09% | 5,584,819 |
| 24-04-23 | 22.75 | +0.04% | 7,525,549 |
| 24-04-22 | 22.74 | +1.02% | 6,167,673 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.19
CNY
Average target price
29.75
CNY
Spread / Average Target
+28.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.35% | 7.65B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600196 Stock
